pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›calendar
  3. ›drug shortage
drug shortage
save

Azacitidine Injection shortage — Bristol Myers Squibb Co.

April 16, 2026$BMYupdated 5mo ago
community read0 votes

Status: Current. Reason: not specified. Form: Injection

view source ↗
Data sources
fda drug shortages
last refreshed 5mo ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

same company · ±60 days · 3

  • earningsBRISTOL MYERS SQUIBB CO earningsApr 30, 2026
  • approvalnivolumab: OPDIVO (NIVOLUMAB) — FDA approvalMar 20, 2026
  • approvalfedratinib: INREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approvalMar 18, 2026

related news · 8

  • biopharma diveCellCentric raises $220M for a ‘transformative’ multiple myeloma medicine↗
  • biopharma diveCytokinetics heart drug scores in closely watched trial↗
  • statUCB to acquire maker of antibody treatments for autoimmune diseases↗
  • biopharma diveUCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases↗
  • biopharma diveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook↗
  • endpointsKrazati fails confirmatory trial in colorectal cancer, putting approval at risk↗
  • statSTAT+: Five-way obesity drug is super effective — in mice↗
  • endpointsAnalysts focus on three programs in big year for Bristol Myers↗

🐶 often sniffed alongside

top 8
  • tagApproval166 co-mentions · 83 sources
  • drugOPDIVO166 co-mentions · 83 sources
  • drugOPDIVO QVANTIG166 co-mentions · 83 sources
  • drugnivolumab166 co-mentions · 83 sources
  • company$CELG-RIBRISTOL MYERS SQUIBB CO84 co-mentions · 84 sources
  • tagDrug Shortage1 co-mentions · 1 sources
  • drugazacitidine1 co-mentions · 1 sources
  • drugOnureg1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?